PatternsRadar
Sign in

BIOCONBiocon Limited

NSEF&O
Full chart
369.10INR-0.70 (-0.19%)Close · 6 Oct 2026
5 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹60,152 CrMarket cap
144.5P/E (TTM)
75.8%Delivery

Filings & corporate actions

81 results filed
CSV
Next results · Q2 FY27
Expected 22 Oct 2026 – 15 Nov 2026
Estimate: filed 22–46 days after quarter end, last 5 times
Dividend
₹0.50 per share · last 3 Jul 2026
2026
  • 5 AugresultsResults · Q1 FY27 · consolidated and standalone+2.7%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+0.9%NSE
  • 3 JuldividendDividend · ₹0.50 per share+2.0%
  • 1 JulshareholdingShareholding · 29 Jun 20260.0%NSE
  • 8 MayresultsResults · Q4 FY26 · consolidated-0.5%NSE
  • 7 MayresultsResults · Q4 FY26 · standalone-0.5%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026+0.7%NSE
  • 12 FebresultsResults · Q3 FY26 · consolidated and standalone+0.8%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025-0.4%NSE
  • 16 JanshareholdingShareholding · 14 Jan 2026-0.4%NSE
  • 6 JanshareholdingShareholding · 5 Jan 2026-1.6%NSE

Reaction to results · all yearsrose on day 0 in 27 of 78 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY275 Aug 2026+2.7%-1.2%-5.5%1.6×
Q4 FY267 May 2026-0.5%+12.5%+7.1%1.8×
Q3 FY2612 Feb 2026+0.8%+2.4%+0.5%1.6×
Q2 FY2611 Nov 2025+5.4%+6.5%-1.5%6.5×
Q1 FY267 Aug 2025-5.7%0.0%+0.1%1.2×
Q4 FY258 May 2025-1.4%+1.4%-1.4%2.0×
Q3 FY2531 Jan 2025+1.6%+11.2%-15.3%1.1×
Q2 FY2530 Oct 2024-1.4%+2.3%+17.0%4.9×
Q1 FY259 Aug 2024-0.6%+1.7%+11.3%2.5×
Q4 FY2416 May 20240.0%+4.5%+9.5%1.0×
Q3 FY249 Feb 2024-2.5%+6.5%+2.1%0.9×
Q2 FY2410 Nov 2023+3.3%+3.3%+4.9%0.6×
Q1 FY2411 Aug 2023-0.6%+1.5%+4.3%1.2×
Q4 FY2324 May 2023-1.3%+0.9%-1.7%1.9×
Q3 FY2315 Feb 2023+2.0%-7.6%-15.0%1.9×
Q2 FY2315 Nov 2022-0.8%-1.3%-7.0%2.0×
Q1 FY2327 Jul 2022-5.1%-2.9%-6.1%6.0×
Q4 FY2229 Apr 2022+1.2%-10.2%-11.1%1.0×
Q3 FY2221 Jan 2022+3.5%+0.8%+6.4%3.9×
Q2 FY2222 Oct 2021-0.8%+7.6%+11.1%1.5×
Q1 FY2223 Jul 2021-2.2%-2.0%-12.2%0.9×
Q4 FY2129 Apr 2021-3.6%-3.2%-1.4%2.3×
Q3 FY2122 Jan 2021-2.8%-0.6%-2.1%2.8×
Q2 FY2123 Oct 2020-3.5%-3.1%+3.9%2.2×
Q1 FY2124 Jul 2020-3.7%-0.8%-5.5%0.8×
Q4 FY2015 May 2020+1.0%+9.1%+17.2%1.3×
Q3 FY2024 Jan 20200.0%0.0%+6.8%2.9×
Q2 FY2024 Oct 2019-1.4%+7.6%+7.9%1.9×
Q1 FY2026 Jul 2019+1.4%-3.1%-4.1%3.3×
Q4 FY1910 May 2019+1.5%-2.0%-0.2%0.9×
Q3 FY1928 Jan 2019-0.1%0.0%-4.5%1.0×
Q2 FY1929 Oct 2018+2.8%+1.1%-3.2%1.0×
Q1 FY193 Aug 2018-1.6%-1.9%+7.1%0.5×
Q4 FY1815 Jun 2018-0.5%+1.7%-6.6%0.5×
Q3 FY1813 Mar 2018+0.3%-3.9%+3.6%1.0×
Q2 FY1830 Oct 2017+2.1%+14.8%+15.6%0.7×
Q1 FY1831 Jul 2017-2.1%-9.0%-12.4%0.7×
Q4 FY1717 May 2017-0.5%-5.9%+4.2%0.8×
Q3 FY1730 Jan 2017-0.9%+7.6%+9.2%0.8×
Q2 FY1724 Oct 2016-3.2%-4.7%-11.3%1.6×
Q1 FY171 Oct 2016+3.3%+1.2%-2.6%0.6×
Q4 FY1627 Apr 2016+1.2%+9.9%+15.0%1.8×
Q3 FY1622 Jan 20160.0%+0.7%-2.3%1.0×
Q2 FY1627 Oct 20150.0%+1.5%+3.2%0.5×
Q1 FY1628 Jul 2015-2.0%+1.7%-7.2%1.0×
Q4 FY159 May 2015+1.5%+3.7%+0.2%0.4×
Q3 FY1523 Jan 2015-0.9%+3.1%+3.0%1.9×
Q2 FY1527 Oct 2014-2.1%-6.1%-4.2%1.0×
Q1 FY155 Aug 2014+1.1%+1.7%+6.2%0.9×
Q4 FY1430 Apr 2014-0.8%+1.6%-9.7%0.6×
Q3 FY1423 Jan 2014-5.7%-3.3%-1.8%1.6×
Q2 FY1428 Oct 2013-0.6%+6.2%+11.8%0.7×
Q1 FY1430 Jul 2013-3.6%-3.7%+5.6%1.2×
Q4 FY1310 May 20130.0%+1.4%-0.1%0.3×
Q3 FY1325 Jan 2013+1.6%+6.7%+9.0%1.2×
Q2 FY1331 Oct 2012+2.4%+11.3%+10.5%2.5×
Q1 FY1326 Jul 2012-5.4%-3.9%-1.0%2.0×
Q4 FY124 May 2012-1.8%-6.8%-10.5%0.9×
Q3 FY1225 Jan 2012-3.4%-3.3%+3.5%2.6×
Q2 FY1220 Oct 2011-0.3%+2.2%-7.8%1.6×
Q1 FY1221 Jul 2011-2.0%-1.9%-12.9%6.2×
Q4 FY1128 Apr 2011-4.0%-7.0%-13.5%4.3×
Q3 FY1120 Jan 2011-2.0%-8.2%-11.1%6.9×
Q2 FY1122 Oct 2010+0.2%-7.2%-8.7%1.1×
Q1 FY1123 Jul 2010-3.1%-6.5%+6.2%4.8×
Q4 FY1029 Apr 2010+2.9%-1.4%-4.1%3.9×
Q3 FY1021 Jan 2010-3.7%-8.0%-8.3%2.3×
Q2 FY1022 Oct 2009+0.6%-8.4%-1.0%3.2×
Q1 FY1023 Jul 2009+3.1%+0.7%+1.0%2.2×
Q4 FY0928 Apr 20090.0%+7.6%+26.2%4.1×
Q3 FY0921 Jan 2009+1.1%-11.0%-8.0%6.6×
Q2 FY0916 Oct 2008-3.7%-6.7%-20.9%1.4×
Q1 FY0917 Jul 2008-6.7%-2.9%+5.6%7.5×
Q4 FY0822 Apr 2008+0.8%-3.0%-6.3%27.2×
Q3 FY0817 Jan 2008-1.4%-28.3%-23.9%1.2×
Q2 FY0818 Oct 2007-1.6%-2.2%+25.1%2.8×
Q1 FY0818 Jul 2007+0.1%-3.0%-5.7%6.5×
Q4 FY0719 Apr 2007-2.6%-7.5%-9.6%2.6×
Average-0.7%-0.5%-0.4%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+10.0%
Profit YoY+53.4%
Interest cost YoY-1.2%
Revenue QoQ-4.0%
Profit QoQ-31.1%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+8.3%+11.6%+19.3%+19.2%+17.5%+16.8%
Profit-54.5%-12.6%-15.9%-12.0%-10.5%-12.9%

Key data

CSV
Open369.70
Day range366.60 – 371.00
52-week range337.05 – 447.15
From 52w high-17.5%
RSI (14)32.7
ATR (14)8.77
Volume46.48L
Avg volume (20D)34.14L
Rel volume1.36×
Volatility (1Y)25.1%
Turnover₹171.6Cr
SMA 50 / 200404.50 / 394.80

Delivery percentage

Latest · 6 Oct 202675.8%
20-day avg51.5%
1-year avg48.5%
Percentile (own history)100th
Range7.8–80.1%
Sessions1,731

Over the last 20 sessions BIOCON settled 51.5% of its traded quantity, which is above average for an NSE equity. Its one-year average is 48.5%, so recent sessions are running 3.0 points higher than usual. The latest session ranks higher than 100% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-0.19%-1.55%-8.18%-9.29%+4.69%+8.91%

Valuation

CSV
Market cap₹60,152 Cr
P/E (TTM)144.5
EPS (TTM)2.56
Shares outstanding162.96Cr
Listed7 Apr 2004

Ownership

CSV
Promoter44.68%
Promoter Δ QoQ0.00 pp
Public55.27%
FII8.14%
DII23.38%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)4,295.54,173.04,516.64,336.0
YoY chg+19.6%+9.2%+2.3%+10.0%
Net profit (₹ Cr)132.8(51.8)198.6136.8
YoY chg+390.0%-163.9%-56.8%+53.4%
Net margin3.1%-1.2%4.4%3.2%
EPS0.651.070.790.87

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 44.68% · public 55.27%
30 Sept 2021: promoter 60.64%31 Dec 2021: promoter 60.64%31 Mar 2022: promoter 60.64%30 Jun 2022: promoter 60.64%30 Sept 2022: promoter 60.64%31 Dec 2022: promoter 60.64%31 Mar 2023: promoter 60.64%30 Jun 2023: promoter 60.64%30 Sept 2023: promoter 60.64%31 Dec 2023: promoter 60.64%31 Mar 2024: promoter 60.64%30 Jun 2024: promoter 60.64%30 Sept 2024: promoter 60.64%31 Dec 2024: promoter 60.64%31 Mar 2025: promoter 60.64%19 Jun 2025: promoter 54.45%30 Jun 2025: promoter 54.45%30 Sept 2025: promoter 54.45%31 Dec 2025: promoter 54.45%5 Jan 2026: promoter 48.27%14 Jan 2026: promoter 44.91%31 Mar 2026: promoter 44.91%29 Jun 2026: promoter 44.68%30 Jun 2026: promoter 44.68%
2021-092026-06
  • Promoter
  • Public and others
Promoter
44.68%
Public
55.27%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
8.14%
DII
23.38%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations3,462.33,953.73,917.13,432.93,590.43,821.44,417.03,941.94,295.54,173.04,516.64,336.0
Other income157.9565.548.61,134.532.534.836.979.793.0117.352.554.5
Total income3,620.24,519.23,965.74,567.43,622.93,856.24,453.94,021.64,388.54,290.34,569.14,390.5
Total expenses3,357.73,708.13,635.23,453.93,550.53,718.43,987.53,924.74,205.34,064.74,241.24,249.4
└ Finance costs247.7266.7227.0236.0225.6223.4212.4276.7272.2209.9231.5213.2
└ Depreciation389.3414.5407.0405.4419.9425.4436.3455.0473.0515.3513.4547.4
Profit before tax238.5832.3321.71,145.598.4155.9486.896.9171.3(67.8)247.5127.6
Tax expense41.654.996.1283.771.374.827.47.738.5(16.0)48.9(9.2)
Net profit172.7753.3222.9861.827.181.1459.489.2132.8(51.8)198.6136.8
EPS1.055.521.135.51-0.130.212.880.260.661.080.790.87
Net margin4.99%19.05%5.69%25.10%0.75%2.12%10.40%2.26%3.09%-1.24%4.40%3.15%
PBT margin6.89%21.05%8.21%33.37%2.74%4.08%11.02%2.46%3.99%-1.62%5.48%2.94%
Tax rate17.44%6.60%29.87%24.77%72.46%47.98%5.63%7.95%22.48%—19.76%-7.21%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.

BIOCON at a glance

  • BIOCON closed at ₹369.1 on 6 Oct 2026, -0.19% on the day, +8.9% over one year, 17.5% below its 52-week high of ₹447.15.
  • Delivery was 75.8% of traded quantity on 6 Oct 2026, the 100th percentile of its own 1,731 sessions with a reading (20-session average 51.5%, 1-year average 48.5%).
  • Market capitalisation is ₹60,152 crore at a trailing P/E of 144.5 (trailing EPS ₹2.56).
  • Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹4,336 crore (+10.0% year on year), net profit ₹137 crore (+53.4%); the price moved +2.7% on the first session after.
  • Promoters held 44.68% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 22 Oct 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE376G01013
SeriesEQ
Listed7 Apr 2004
History from7 Apr 2004
Sessions5,581
Turnover rank#241

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE